Adoptive transfer of CD8 T cells has the potential to cure infectious or malignant diseases that are refractory to conventional chemotherapy. A practically important but still unanswered question is whether mixtures of protective CD8 T cells with different epitope specificities mediate more efficient effector cell functions than do the monospecific individual CD8 T cell populations. In this study, we have addressed this issue for models of viral and bacterial infection. CD8 T cell-mediated cytotoxicity in vitro and protection in vivo were assessed to test whether CD8 T cell lines cooperate in target cell lysis and control of infection, respectively. Our data clearly show that mixtures of cytolytic T cell lines specific for different epitopes of either murine cytomegalovirus or Listeria monocytogenes do not act synergistically. An efficient anti-infectious protection thus proved to be dependent primarily on the number of transferred protective CD8 T cells rather than on the cooperative effects of multiple specificities.
In passive T cell immunotherapy, T cell clones or lines are directly administered to patients. Immunotherapy with cytolytic CD8 T cell (cytotoxic T lymphocyte [CTL] ) lines (CTLLs) is currently a therapeutic option for the treatment of viral [1] and malignant diseases in humans [2] . It is frequently used for the treatment of immunosuppressed patients who are seriously ill from infection with Epstein-Barr virus, HIV, or human cytomegalovirus (hCMV) [3, 4] .
Patients with malignant disease and transplant recipients often receive highly toxic and immunosuppressive chemotherapy. These regimens are frequently associated with reactivation of latent viruses as well as with a failure in generating pathogen-or tumor-specific effector cells. Adoptive transfer of effector cells grown in vitro can bypass the problems associated with immunosuppressive therapy. On the other hand, monospecific effector cell populations insufficiently represent the complexity of the naturally occurring immune response. This might limit the efficacy of adoptive immunotherapy.
The major obstacles to routine clinical application of cellular immunotherapy are the generation of sufficient numbers of effector cells in vitro as well as the often poor expansion and limited survival of transferred CTLs in vivo. Numerous studies have been performed to prolong the survival and to enhance the effector functions of adoptively transferred CTLs, for example, by coadministration of T helper cells, cytokines, or costimulatory antibodies (reviewed in [3] [4] [5] ).
Another theoretical limitation of adaptive immunotherapy is the specificity spectrum of the transferred CTLLs or CTL clones. Because of clonal selection in cell culture, effector cells propagated in vitro usually exhibit a more-restricted specificity repertoire compared with a naturally occurring immune response. This is particularly evident in the case of a monospecific CTLL raised against a single antigenic peptide.
A number of studies aimed at vaccination against murine cytomegalovirus (mCMV) [6 -8] as well as against Listeria monocytogenes as model systems [9] have shown that simultaneous immunization with multiple T cell antigens mediates superior protection compared with immunization with a single T cell antigen. To our knowledge, however, the important issue of whether superior protection is mediated by the cooperation of different T cell specificities has not yet been studied systematically in an adoptive transfer model with CTLLs.
The infection of mice with mCMV is an established animal model that in many aspects mimics the infection of humans with hCMV [10, 11] [14] as well as against a number of other epitopes [10, 11] . With the exception of the IE1-derived antigenic peptide, which is already detectable in the immediate early phase of viral gene expression, the other currently known mCMV-derived viral epitopes are not presented before the early phase [10, 11] .
The infection of mice with L. monocytogenes is one of the best studied models of bacterial infection and is used for the investigation of all aspects of innate and cell-mediated immunity [15] . In BALB/c mice, L. monocytogenes infection stimulates immunodominant K d -restricted CTL responses against aa 217-225 of the bacterial murein hydrolase p60 [16] and against aa 91-99 of listeriolysin O [17] . Significantly weaker subdominant K drestricted CTL responses are directed against peptides p60 449 -457 [18] and p60 476 -484 [19] .
In the present study, we have addressed the question of whether CTLs specific for different epitopes cooperate in their effector functions. Our data clearly demonstrate that, in both viral and bacterial infection models, in vitro target cell lysis and in vivo protection cannot be improved by using mixtures of 2 monospecific CTLLs. Thus, adoptive antiviral and antibacterial protection mediated by protective CD8 T cells appears to depend primarily on the number of transferred cells.
MATERIALS AND METHODS
Mice and infection of mice. For mCMV infection, female BALB/c (H-2 d ) mice were bred and housed under specifiedpathogen-free conditions in the Central Laboratory Animal Facility of the Johannes Gutenberg-Universität Mainz and were used at an age of 8 -9 weeks. Animal experiments were approved under permission number 177-07/021-28, according to German federal law.
Intraplantar infection of immunocompromised mice with 10 5 pfu of cell culture-propagated, sucrose density gradient-purified mCMV strain Smith (ATCC VR-194, reaccessioned as VR-1399) was done as described elsewhere [20] . For L. monocytogenes infection, female BALB/c (H-2 d ) mice were purchased (Janvier), kept under conventional conditions, and used at 8 -10 weeks of age. Animal experiments were approved under permission number G-3/06. Mice were infected intravenously (iv) with L. monocytogenes serovar 1/2a EGD in 0.2 mL of PBS. Bacteria used for infection were in the logarithmic growth phase. The bacterial concentration was estimated on the basis of the optical density at 600 nm.
Peptides. Custom peptide synthesis to a purity of Ͼ75% was performed by Jerini Peptide Technologies. Synthetic peptides were used for the generation of CTLLs as well as for the exogenous loading of target cells in the cytolytic assay.
CTLLs and CTLL mixtures. Polyclonal CTLLs specific for mCMV peptides IE1 168 -176 , m164 257-265 , m145 [451] [452] [453] [454] [455] [456] [457] [458] [459] , and m18 346 -354 were generated by repeated stimulation of memory spleen cells with synthetic peptides, as described in greater detail elsewhere [13] . Briefly, spleen cells derived from BALB/c mice Ͼ3 months after mCMV infection were repeatedly stimulated in the presence of the indicated peptides at 10 Ϫ9 mol/L, except for peptide m18 346 -354 , which was used at 10 Ϫ10 mol/L.
CTLLs specific for p60 217-225 , p60 449 -457 , and LLO 91-99 were generated from spleen cells from L. monocytogenes-infected BALB/c mice 2 weeks after infection. CTLLs were propagated by repeated stimulation in the presence of 10 Ϫ9 mol/L peptide, as described in detail elsewhere [21] . CTLL mixtures were prepared by mixing 2 CTLLs of different specificities at a 1:1 ratio with the total cell number kept constant.
In vitro cytotoxicity assay. The cytolytic activity of mCMV-specific CTLs was measured in a standard 4-h 51 Cr release assay with 1000 51 Cr-labeled targets at the effector to target cell (E:T) ratios indicated. Target cells were either DBA/2 (H-2 d ) mouse-derived P815 mastocytoma cells exogenously loaded with synthetic peptides or BALB/c mouse embryonic fibroblasts (MEFs) centrifugally infected with 0.2 pfu of mCMV per cell in the presence of phosphonoacetic acid (PAA) [20] . PAA arrests viral replication in the early phase of viral gene expression. After infection, MEFs were incubated for 22 h until they were labeled and used as target cells. Data represent the mean percentage of specific lysis from 3 replicate cultures.
The 51 Cr release assays with L. monocytogenes-infected target cells were performed as described elsewhere [21] , with 2000 target cells at the E:T ratios indicated. Adherent J774 cells were infected at an MOI of 10 for 30 min. After infection, cells were washed and cultured in the presence of 15 g/mL gentamicin in the culture medium. After 90 min, cells were detached by trypsin and labeled for 90 min with 51 Cr. For peptide-loading experiments, P815 target cells were used.
Adoptive transfer. Adoptive transfer experiments with mCMV-specific CTLs were performed as described elsewhere [22] . In brief, BALB/c transfer recipient mice were immunocompromised by hematoablative ␥-irradiation, with a single dose of 6.5 Gy delivered by a cesium 137 ␥-ray source. Cell transfer was performed ϳ4 h later by iv infusion in 0.5 mL of physiological saline, using CTLLs specific for IE1 168 -176 or m164 257-265 or a 1:1 mixture of both. CTLLs were used after 3 rounds of restimulation. This selection period is required to reach epitope monospecificity of CTLs but is still short enough not to lose expression of coreceptor CD8 and polyclonality, as defined by broad T cell receptor chain variable region (V␤) usage [23] . Subsequently, intraplantar infection was performed with 10 5 pfu of mCMV in 25 L of physiological saline, as described elsewhere [20] . Infectious virus, measured in plaque-forming units, was quantified in organ homogenates by a plaque assay on MEFs with centrifugal enhancement of infectivity [20] .
For adoptive transfer experiments with L. monocytogenesspecific CTLs, mice were infected iv with 10 4 cfu of L. monocytogenes and subsequently received graded numbers of peptidespecific CTLs iv in PBS as indicated. The number of colonyforming units in the organ homogenates was determined 72 h later by pour plating dilutions of bacteria in brain-heart infusion agar.
Statistical analysis. The statistical significance of the results of adoptive transfer experiments was analyzed with the Tukey multiple comparison test [24] at the .05 significance level after logarithmic transformation of colony-forming and plaqueforming unit values. This test analyzes the significance of the difference between all possible pairs of means with appropriate adjustment for the multiple testing. Calculations were performed using WINKS statistical analysis software (version 4.70; TexaSoft).
RESULTS

CTL-mediated lysis of peptide-loaded target cells.
To study whether CTLs cooperate synergistically in target cell lysis, we In essence, the target cell lysis obtained with mixtures of 2 CTLLs was as strong as the lysis obtained with the superior individual CTLL. As intended, the peptide sensitivity and the maximum target cell lysis of the 2 individual CTLLs of a mixture were quite similar. Furthermore, target lysis was found to be almost identical regardless of whether a CTLL was tested individually or in a mixture with another CTLL. In only 1 combination, namely, IE1 168 -176 -specific plus m164 257-265 -specific CTLs, the killing of peptide-loaded target cells by the individual CTLL differed significantly. Although IE1 168 -176 -specific CTLs were 100-fold more sensitive, m164 257-265 -specific CTLs showed a higher maximum target cell lysis ( figure 1, upper panel) . At high concentrations of the peptide mixture, the maximum target cell lysis by IE1 168 -176 -specific plus m164 257-265 -specific CTLs was as high as the lysis by m164 257-265 -specific CTLs alone, whereas at lower peptide concentrations the sensitivity of peptide recognition mirrored the sensitivity of the IE1 168 -176 -specific CTLL.
These findings clearly indicate that the cytolytic potential of a CTL mixture-with regard to the parameters of maximum target cell lysis and sensitivity-reflects the potential of the superior CTLL of the mixture. If the individual CTLLs are similar with respect to those parameters, the mixture does not show an improved effector function.
CTL lysis of infected target cells. To confirm the lack of synergistic effects during the in vitro lysis of peptide-loaded target cells, we also tested the lysis of infected cells presenting naturally processed peptides. For this, MEFs were infected with mCMV and were subsequently used as target cells for individual CTLLs and mixtures thereof (figure 3). In accordance with the absence of functional synergy, lysis of mCMV-infected fibroblasts by CTLL mixtures was not more efficient than lysis by the superior individual CTLL alone.
The lysis of L. monocytogenes-infected macrophage-like J774 cells gave similar results. Specifically, lysis of L. monocytogenesinfected cells by CTLLs could not be improved by mixing 2 different CTL specificities (figure 4). Taken together, the data de-
Figure 2. Lysis of peptide-loaded target cells by Listeria monocytogenes-specific cytotoxic T lymphocyte (CTL) lines (CTLLs).
51 Cr-labeled P815 cells were loaded either with a single peptide or with a mixture of 2 different peptides at the indicated molar concentrations and were used as target cells in a standard 51 Cr release assay. Peptide concentrations in mixtures refer to each individual peptide. Effector cells were either an individual L. monocytogenes-specific CTLL or mixtures of 2 CTLLs with different specificities. Target cell lysis was tested at a constant final effector to target cell ratio of 10:1. The mean percentage of specific lysis of target cells is shown, calculated from triplicate assay cultures. All experiments were repeated twice, with similar results.
rived from 2 infection models strongly suggest that CTLs do not act synergistically during target cell lysis in vitro.
Protection of mice by adoptive CTL transfer. To test a possible in vivo cooperative effect of CD8 T cells specific for different antigenic peptides derived from the same pathogen, adoptive transfer experiments were performed in both infection models. Specifically, recipient mice were infected with mCMV or with L. monocytogenes, and graded numbers of peptidespecific CTLLs were transferred. Adoptive transfers were performed either with a CTLL of a single specificity or with mixtures of 2 CTLLs specific for different epitopes.
For the treatment of mCMV-infected mice, we chose the combination of IE1 168 -176 -specific and m164 257-265 -specific CTLs, because in this particular combination the CTL mixture indeed complemented the in vitro cytolytic properties of the 2 individual CTLLs ( figure 1, upper panel) . Adoptive transfer of 10 5 or 10 6 monospecific CTLs yielded significant (by the Tukey multiplecomparison test at P Ͻ .05) antiviral protection in the spleen (figure 5A) and lungs (figure 5B), whereas lower cell numbers were not sufficient. In the spleen, 10 6 IE1 168 -176 -specific CTLs were significantly more protective than 10 6 -specific m164 257-265 CTLs. After transfer of 10 5 cells, protection mediated by the 2 individual CTLLs did not differ significantly, neither in the lungs nor in the spleen. Importantly, cotransfer of both CTLLs in a 1:1 mixture did not significantly improve the protective potential above the level obtained with the strongest individual CTLL alone ( figure 5A and 5B).
Likewise, significant antibacterial protection against L. monocytogenes infection in the spleen required adoptive transfer of a minimum of 10 5 LLO 91-99 -specific or 10 6 p60 217-225 -specific CTLs (figure 6A). Significant protection in the liver was observed only after transfer of a minimum of 10 6 LLO 91-99 -specific or 10 7 p60 217-225 -specific CTLs (figure 6B). LLO 91-99 -specific CTLs tended to be more protective than p60 217-225 -specific CTLs, but this trend was not statistically significant. Similar to the situation after adoptive transfer of mCMV-specific CTLs, a 1:1 mixture of LLO 91-99 -specific and p60 217-225 -specific CTLs was not more protective than LLO 91-99 -specific CTLs alone (figure 6A and 6B).
DISCUSSION
Our data clearly show that individual monospecific cytolytic CD8 T cell lines with different specificities do not synergistically reinforce each other in their effector functions. Target cell lysis in vitro and protective potential in vivo mediated by mixtures of 2 CTLLs were generally not significantly improved compared with the effects obtained with the stronger CTLL alone.
Theoretically, the effect of a combination of 2 CTL populations could be synergistic, additive, or antagonistic. For instance, an increased chance of detecting an infected cell presenting different antigens with different kinetics could lead to synergism, whereas competition at the immunological synapse may result in antagonism. Our data, however, did not provide any evidence for a CD8 T cell antagonism. Rather, the data indicate that the combined action of 2 individual peptide-specific CTLLs can be described most precisely as additive. The additive effect is suggested by the finding that the effect of CTLL mixtures was not lower than the effect of the stronger partner in the combination, although the number of cells of each line was reduced by half in the mixture. The maximum target cell lysis as well as the maximum protection achieved by combinations of CTLLs were largely determined by the stronger CTLL. In the combination of IE1 168 -176 -specific plus m164 257-265 -specific CTLs, the sensitivity and the maximum target cell lysis of the 2 CTLLs differed largely. The m164 257-265 -specific CTLs were less sensitive than the IE1 168 -176 -specific CTLs in terms of threshold concentration of peptide but nevertheless led to a higher maximum lysis. In this particular combination, the CTLL mixture indeed complemented the properties of the 2 individual CTLLs, leading to high sensitivity and high lytic activity. In no instance, however, could a synergistic cooperation of 2 CTLLs be observed. One would have expected to detect synergy primarily between CTLLs of comparable functional avidity and lytic potential-as was the case for the combinations of mCMV m18 345-354 plus m164 257-265 , mCMV m18 345-354 plus m145 [451] [452] [453] [454] [455] [456] [457] [458] [459] , and L. monocytogenes p60 217-225 plus LLO 91-99 -yet the lytic activity and protective potential of the mixed CTLL population did not exceed those of the individual monospecific CTLL. The results of the in vivo experiments presented here are applicable only to passive T cell immunotherapy and may not be used to predict the effect of the combination of multiple antigens during active T cell immunization. Vaccination studies in the murine infection models with mCMV [6 -8] and L. monocytogenes [9] have clearly shown that active priming of an immune response against multiple CD8 T cell antigens results in a synergistic protective T cell response in vivo.
In contrast, in the adoptive transfer model the comparison of individual monospecific CTLLs and mixtures of CTLLs has revealed no synergistic but also no inhibitory interactions. It is known that adoptively transferred CTLLs directed against dominant as well as subdominant antigenic peptides derived from mCMV [11, 13, 25, 26] and L. monocytogenes [27] ). Yet, for the various CTLL mixtures tested, we could not detect any influence of either the immunodominance status or the MHC class I restriction of the CTLL on effector function in vitro or in vivo. In addition, the experiments with target cells loaded with 2 peptides presented by the same MHC class I molecule did not reveal any hint of peptide competition for MHC binding sites in the broad peptide concentration range tested. Therefore, antigen presentation and target cell recognition were limited neither by peptide binding to MHC class I molecules nor by the availability of peptide or MHC complexes on the surface of the target cells.
The use of monospecific CD8 T cell populations for the treatment of infections or tumors risks the rapid development of resistance to therapy, owing to the selection of escape mutations. This mechanism of immune escape from CTLs is well documented for HIV [28] as well as for metastatic melanomas [29, 30] but has not been documented for either genetically stable DNA viruses, such as mCMV and hCMV, or bacteria in general. Nevertheless, transferring Ͼ1 CTL specificity increases the safety margin and is therefore favored clinical practice. Although our data indicate that in this situation a synergistic effect is unlikely, the approach is nevertheless justified as a security measure, because antagonistic effects of the transferred CD8 T cells are not expected.
In conclusion, our data have shown that with therapeutic adoptive transfer regimens the total number of transferred effector cells is more important than the combination of multiple specificities. This finding might be useful for the future design of more economic adoptive transfer protocols.
